Cellenkos Wins FDA Clearance for CK0801 Phase 2 Trial

HOUSTON, TEXAS, April 27, 2026

Cellenkos Inc. has received U.S. Food and Drug Administration (FDA) clearance to initiate a Phase 2 clinical trial for CK0801, an innovative allogeneic cord blood-derived regulatory T cell (Treg) therapy targeting patients with transfusion-dependent aplastic anemia. This milestone marks a significant advancement in cell and gene therapy development, addressing a critical unmet need in a rare and life-threatening hematological disorder where current treatment options remain limited.

FDA Clearance Advances Next-Generation Cell Therapy

The FDA clearance enables the launch of a multicenter, open-label Phase 2 study designed to evaluate the safety and clinical efficacy of CK0801, with a focus on reducing transfusion dependence in patients who have failed standard therapies. The study will assess a primary endpoint of achieving at least a 30% reduction in transfusion requirements by Day 180, providing a meaningful measure of therapeutic impact.

Aplastic anemia is a severe autoimmune condition characterized by bone marrow failure, leading to a deficiency of red blood cells, white blood cells, and platelets. Many patients, particularly older individuals and those without suitable donors for transplantation, are left with limited treatment options and often rely on chronic blood and platelet transfusions, significantly affecting their quality of life.

The advancement of CK0801 into Phase 2 represents a critical step toward developing a potentially transformative therapy, offering hope for patients who currently have few alternatives beyond supportive care.

Innovative Treg Therapy Targets Immune Dysregulation

CK0801 is developed using proprietary technology to generate enhanced “supercharged” regulatory T cells, designed to restore immune balance and address the underlying autoimmune mechanisms driving aplastic anemia. Derived from healthy allogeneic cord blood, the therapy aims to modulate the immune system and promote bone marrow recovery, rather than simply managing symptoms.

The therapy works through multiple mechanisms, including reducing inflammatory immune cells, restoring immune homeostasis, and enabling regeneration of healthy blood cells, offering a comprehensive approach to disease modification. This innovative strategy positions CK0801 as a potential disease-modifying and curative treatment, rather than a temporary intervention.

Early Phase 1 data demonstrated a favorable safety profile and promising clinical activity, with no severe treatment-related adverse events reported and evidence of durable transfusion independence in some patients. These findings support the continued development of CK0801 and highlight its potential to deliver long-term benefits.

Addressing Unmet Needs in Rare Hematologic Disorders

Aplastic anemia remains a challenging condition with significant unmet medical needs, particularly for patients who are not eligible for bone marrow transplantation or who do not respond to immunosuppressive therapies. The disease can be life-threatening if untreated, with severe complications arising from infections and bleeding due to low blood cell counts.

CK0801’s development reflects a broader shift toward advanced cell therapies that target the root causes of disease, offering more precise and effective treatment options. The therapy has also received Orphan Drug Designation, underscoring its potential to address a rare condition with limited therapeutic alternatives.

From a cGxP perspective, the FDA clearance highlights the importance of rigorous clinical evaluation, regulatory compliance, and advanced manufacturing processes in the development of cell-based therapies, ensuring safety, quality, and consistency in complex biologic products.

Cellenkos’ continued progress in clinical development and its focus on innovative immune-modulating therapies position it as a key player in the evolving bio-pharma landscape, with the potential to redefine treatment paradigms for autoimmune and inflammatory diseases.

Source: Cellenkos press release